is a novel antimicrobial / antithrombotic therapy that demonstrates
rapid, broad spectrum efficacy and biofilm prevention and elimination.
In in-vitro studies, Zuragen™ has proven effective against
both gram positive and negative strains of bacteria including S.
Aureus, S. Epidermidis, P. Aeruginosa and E. Coli. Considered a combination
therapy (drug / device) by the Food & Drug
Administration, Zuragen™ is currently being evaluated in a
large scale pivotal trial to be completed in 2008.
ZuragenTM is an injectable therapy consisting of unique components that when used together demonstrate a powerful synergy which leads to enhanced efficacy vs. the components alone. The concentrations of the components used in our formulation are significantly less than the concentrations that each component is currently being used in medical practice today. A preliminary FDA approved “safety” study of a key ZuragenTM component demonstrated no adverse events at the concentrations that are incorporated into the final therapeutic solution.
The pivotal trial consists of 415 patients and 25 study sites across the country. Patient enrollment was completed in December, 2007.